澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

医药生物股

569.775

-6.316-1.10%

涨家数：7

跌家数：14

平家数：24

市盈率：- -

高：572.746

开：566.614

低：561.386

收：576.090

成交量：5,615.06万

成交额：1.74亿

市值：782.23亿

流通市值：755.53亿

数据加载中...

总览新闻资讯

Genetic Technologies Ltd 董事会终止收购谈判，集中精力推进重新上市战略机遇

Clinuvel Pharmaceuticals预计上半年有望实现纳斯达克二级ADR上市

CSL 表示出血性疾病基因疗法全球缺货

CSL有限公司正与监管机构协作制定策略确保Hemgenix持续稳定供应

BUZZ-精密生物季度业绩超预期后上涨

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK7508/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"医药生物股","latestPrice":569.7745,"timestamp":1774587599901,"preClose":576.0902,"halted":0,"volume":56150588,"delay":0,"changeRate":-0.010963,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-6.315735,"latestTime":"03-27 16:00:00 AEDT","open":566.6139,"high":572.7464,"low":561.3856,"amount":174489547,"amplitude":0.01972,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1774825200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774566000000,1774587600000]],"turnoverRate":0.002157,"increases":7,"decrements":17,"flats":19,"marketCap":78223041730.75,"floatMarketCap":75552955431.4375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":572.7464,"amplitude":0.01972,"preClose":576.0902,"low":561.3856,"latestPrice":569.7745,"volume":56150588,"delay":0,"open":566.6139,"prevYearClose":644.3692,"prevWeekClose":551.995,"prevMonthClose":592.49,"prevQuarterClose":644.369,"fiveDayClose":551.995,"twentyDayClose":592.49,"sixtyDayClose":644.369,"secType":"PLATE","market":"AU","turnoverRate":0.002157,"marketCap":78223041730.75,"floatMarketCap":75552955431.4375,"timestamp":1774587599901,"nameCN":"医药生物股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":7,"down":14,"flat":24},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1108522577","title":"Genetic Technologies Ltd 董事会终止收购谈判，集中精力推进重新上市战略机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=1108522577","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108522577?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 09:36","pubTimestamp":1774316179,"startTime":"0","endTime":"0","summary":"Genetic Technologies Ltd 董事会已决定终止当前所有收购相关讨论。公司未来将把战略重心转向评估并把握重新上市的潜在机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GTG.AU","BK7508","BK7048"],"gpt_icon":0},{"id":"1173800175","title":"Clinuvel Pharmaceuticals预计上半年有望实现纳斯达克二级ADR上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1173800175","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173800175?lang=zh_cn&edition=fundamental","pubTime":"2026-03-20 05:32","pubTimestamp":1773955968,"startTime":"0","endTime":"0","summary":"生物制药企业Clinuvel Pharmaceuticals Ltd近日释放积极信号，其管理层透露公司正积极推进在纳斯达克交易所的二级美国存托凭证（ADR）上市计划。根据最新表态，这一资本市场的关键布局有望于今年上半年内取得实质性进展。\n若该计划顺利落地，将成为Clinuvel拓展北美投资者基础、提升全球资本市场能见度的重要里程碑。二级ADR的上市通常意味着公司需满足更严格的披露要求，同时也为国际投资者参与其成长故事开辟更便捷的通道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2620471351","title":"CSL 表示出血性疾病基因疗法全球缺货","url":"https://stock-news.laohu8.com/highlight/detail?id=2620471351","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620471351?lang=zh_cn&edition=fundamental","pubTime":"2026-03-18 00:37","pubTimestamp":1773765430,"startTime":"0","endTime":"0","summary":"路透3月17日 - 澳大利亚CSLCSL.AX公司表示，其出血性疾病基因疗法Hemgenix面临暂时性全球缺货，这将推迟该药物在已上市国家的部分患者的治疗。医生们认为，高昂的价格、物流问题和潜在的治疗进展前景阻碍了血友病基因疗法的采用。CSL表示，推迟治疗可能会影响到一些符合条件的患者，这些患者原本计划在已上市的国家接受一次性治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL4T4051K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","IE0002270589.USD","LU0868494617.USD","LU0225771236.USD","LU0321505868.SGD","BK4534","LU0225284248.USD","LU0306807586.USD","BK4568","IE00BBT3K403.USD","BK4581","LU1066053197.SGD","SG9999001176.USD","IE00BLSP4452.SGD","IE000M9KFDE8.USD","LU1066051498.USD","BK7508","SGXZ57979304.SGD","SG9999013999.USD","LU1023059063.AUD","IE00B19Z3581.USD","LU0456855351.SGD","BK7501","LU1894683348.USD","LU1057294990.SGD","BK4533","SG9999002224.SGD","LU0321505439.SGD","SG9999002232.USD","CSL.AU","BK7511","LU1883839398.USD","LU0985481810.HKD","BK4599","BK4550","IE00BLSP4239.USD","BK7067","LU1894683264.USD","IE00B19Z3B42.SGD","BK4585","BK4588","LU0122379950.USD","LU0170899867.USD","LU0234572021.USD","SG9999011175.SGD","BK4592","SG9999001176.SGD","LU0289739699.SGD","LU0058720904.USD","BK4007","SG9999003800.SGD"],"gpt_icon":0},{"id":"1128210509","title":"CSL有限公司正与监管机构协作制定策略 确保Hemgenix持续稳定供应","url":"https://stock-news.laohu8.com/highlight/detail?id=1128210509","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128210509?lang=zh_cn&edition=fundamental","pubTime":"2026-03-17 23:47","pubTimestamp":1773762439,"startTime":"0","endTime":"0","summary":"全球生物技术巨头CSL有限公司近日宣布，公司已启动与相关药品监管部门的密切沟通，共同探讨保障基因疗法Hemgenix长期稳定供应的战略方案。这一举措旨在应对潜在供应链挑战，确保这款突破性血友病B治疗药物能够持续满足全球患者的临床需求。通过建立多方协作机制，CSL将优化从原料采购到成品配送的全链条管理。此次战略合作凸显了CSL对患者用药可及性的长期承诺。CSL将通过技术创新与监管协作的双重路径，持续推动罕见病治疗领域的进步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","CSL.AU","BK7508","BK7501","BK7067"],"gpt_icon":0},{"id":"2618513406","title":"BUZZ-精密生物季度业绩超预期后上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2618513406","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618513406?lang=zh_cn&edition=fundamental","pubTime":"2026-03-12 20:37","pubTimestamp":1773319069,"startTime":"0","endTime":"0","summary":"** 公布第四季度收入为 3420 万美元，超过分析师预期的 910 万美元** 称营收增长主要得益于诺华合作协议中的 2620 万美元和 Imugene 许可协议中的 800 万美元** 2025 年 DTIL 股价上涨超过 9%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nL4S4001AE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMU.AU","DTIL","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}